Tseng, S.-JaS.-JaTsengYang, Pan-ChyrPan-ChyrYangKempson I.M.Li H.-J.S.-JA TSENGPAN-CHYR YANG2020-12-022020-12-0220200168-3659https://www.scopus.com/inward/record.uri?eid=2-s2.0-85085949121&doi=10.1016%2fj.jconrel.2020.05.043&partnerID=40&md5=e1a6599cd4ef5f4588fe0de0b36ba6c1https://scholars.lib.ntu.edu.tw/handle/123456789/523422[SDGs]SDG3Amino acids; Biological organs; Cell signaling; Drug products; Enzyme inhibition; Acquired resistance; Clinical efficacy; Efficient treatment; Epidermal growth factor receptors; Non small cell lung cancer; Sustained release; Therapeutic outcomes; Tyrosine kinase inhibitor; Diseases; antineoplastic agent; epidermal growth factor receptor; lactic acid; nanocarrier; nucleic acid; plasmid DNA; protein tyrosine kinase inhibitor; virus vector; EGFR protein, human; epidermal growth factor receptor; protein kinase inhibitor; cancer immunotherapy; cancer resistance; cytoreductive surgery; DNA transfection; drug formulation; gene mutation; human; in vitro study; in vivo study; metastasis; nanopharmaceutics; nanotechnology; non small cell lung cancer; nonhuman; oncolytic virotherapy; priority journal; Review; RNAi therapeutics; sustained drug release; treatment outcome; tumor microenvironment; drug resistance; genetics; lung tumor; mutation; non small cell lung cancer; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitorsreview10.1016/j.jconrel.2020.05.043324975702-s2.0-85085949121